Supporting Information

A solution ¹⁷O-NMR approach for observing an oxidized cysteine residue in Cu,Zn-superoxide dismutase

Shinya Hanashima,^{*ab*} Noriko Fujiwara,^{**c*} Kana Matsumoto,^{*a*} Noriyuki Iwasaki,^{*d*} Guo-qing Zheng,^{*e*} Hidetaka Torigoe,^{*f*} Keiichiro Suzuki,^{*c*} Naoyuki Taniguchi^{*bgh*} and Yoshiki Yamaguchi^{**ab*}

^a Structural Glycobiology Team, RIKEN ASI, Saitama 351-0198, Japan

^b Disease Glycoprobe Team, RIKEN-Max Planck Joint Research Center, RIKEN ASI, Saitama 351-0198, Japan

^c Department of Biochemistry, Hyogo College of Medicine, Hyogo 663-8501, Japan

^d Bruker Daltonics K.K., Kanagawa 221-0022, Japan

^e Department of Physics, Okayama University, Okayama 700-8530, Japan

^f Department of Applied Chemistry, Faculty of Science, Tokyo University of Science, Tokyo 162-8601, Japan

g Disease Glycomics Team, RIKEN ASI, Saitama 351-0198, Japan

^h The RIKEN-Osaka University Alliance Laboratory, The Institute of Scientific and Industrial Research, Osaka University, Osaka 565-0871, Japan

*Corresponding authors: noriko-f@hyo-med.ac.jp, yyoshiki@riken.jp

Contents

1. Experimental procedures	3
2. Peptide mapping and MS analysis of ¹⁷ O ₂ -oxidized SOD1	4
3. ¹ H-NMR and CD spectra of ¹⁷ O-oxidized SOD1 in Cu ²⁺ ,Zn ²⁺ - and Cu ⁺ ,Zn ²⁺	+-states 5
4. Supporting figures	7
5. References	14

1. Experimental procedures

¹⁷O-labeling with ¹⁷O₂-gas

Recombinant human SOD1 (residues 1-153) chemically modified with 2-mercaptoethanol (2-ME) at Cys¹¹¹ (Cys¹¹¹-S-S-CH₂CH₂OH), designated as 2-ME-SOD1 4, was kindly provided by Ube Industries Ltd. Preparation of Wild-type(WT)-SOD1 1 and ¹⁶O₂-oxidized SOD1 were performed according to previously reported protocols.¹ WT-SOD1 (Cys¹¹¹-SH form) **1** was initially prepared from 2-ME-SOD1 4 by incubation with excess 2-ME for 1 h on ice and then the excess 2-ME was removed using a PD-10 column (GE Healthcare). For labeling with ¹⁷O₂-gas. the WT-SOD1 in milliQ water was degassed and then stirred under ¹⁷O₂ (70% isotope enrichment, ISOTEC) for 24 h at room temperature. The vacuum level was monitored with a vacuum gauge, and the loading of ${}^{17}O_2$ -gas was repeated three times. This oxidation process produced a SOD1 mixture of Cys¹¹¹-SH 1, Cys¹¹¹-SO₂H 2 and Cys¹¹¹-SO₃H **3**.

Peptide mapping and mass spectrometry

The ¹⁷O-labeled position and labeling ratio at Cys¹¹¹ of SOD1 were confirmed by peptide mapping according to previously reported protocols.^{1, 2} Briefly, 0.05 mM SOD1 (calculated as monomer) was incubated in 50 mM Tris-HCl, pH 8.5, including 10 mM EDTA and 7 M guanidinium hydrochloride and 50 mM dithiothreitol (DTT) at The liberated sulfhydryl groups were alkylated with 90 mM 37 °C for 2 h. iodoacetamide in the dark for 30 min at room temperature. After the reaction, the mixture was desalted by dialysis against 50 mM Tris-HCl buffer, pH 8.5. Then, the protein was digested with 0.25% (w/w) lysylendopeptidase (Wako Pure Chemicals) at 37 °C for 16 h. The resultant peptide mixture was fractionated by high performance liquid chromatography (HPLC) with a reverse phase octadecylsilyl modified column (Inertsil ODS3, 4.6 mm×250 mm, particle size: 5 µm; GL Science) at a flow rate of 1.0 Two linear gradients of 0-30% acetonitrile for 4 column volumes and mL/min. 30-40% acetonitrile for 8 column volumes containing 0.05% (v/v) trifluoroacetic acid were employed for separation and the peptides were detected by absorbance at 215 nm. The fractions corresponding to Asp92-Lys122 were subjected to ESI-TOF-MS analysis for estimation of the ¹⁷O enrichment ratio on Cys¹¹¹. High resolution ESI-TOF-MS measurements were performed using maXis (Bruker Daltonics). Each peptide sample was dissolved in 0.08% (v/v) formic acid / 20% (v/v) acetonitrile solution. MS spectra were collected with positive mode.

¹*H*- and ¹⁷*O*-*NMR* spectroscopy

All NMR spectra were collected with Bruker DRX-600 spectrometer equipped with triple resonance inverse (TXI; for ¹H detection) or broad band observation (BBO; for ¹⁷O detection) probes. Water signals in ¹H-NMR spectra were suppressed using a watergate pulse sequence. Chemical shifts of ¹H were referenced to the outer standard 4,4-dimethyl-4-silapentane-1-sulfonic acid (DSS) signal at 0 ppm. ¹⁷O-NMR spectra were measured with aring pulse sequence to cancel acoustic ringing.³ The chemical shifts of ¹⁷O were referenced to the naturally abundant $H_2^{17}O$ signal at 0 ppm. The ¹⁷O-NMR spectra were accumulated from 500 k to 1,000 k scans, and FID data were treated upon multiplication by an exponential function with a 150 Hz line broadening factor. The protein or peptides was dissolved in 20 mM sodium phosphate buffer (pH 5.0) containing 10% (v/v) D_2O_2 , and probe temperature was set at 20 °C during the NMR experiments. The Cu²⁺-form of ¹⁷O₂-oxidized SOD1 was reduced to produce the Cu⁺-form using 10 mM 2-ME or 10 mM isoascorbic acid. Under the reducing conditions, the blue color of the SOD1 solution gradually faded, and finally became colorless. The time course of the reduction by 2-ME was followed by observing the fingerprint His-region of ¹H-NMR spectra. A digested peptide form was prepared according to the above-mentioned peptide mapping procedures. ¹H- and ¹⁷O-NMR spectra of the peptide form were collected before HPLC fractionation.

CD spectroscopy

¹⁶O₂-oxidized SOD1 (116 μ M) in 20 mM phosphate buffer (pH 5.0) was incubated alone or in the presence of 10 mM 2-ME for 16 h at room temperature and each sample was diluted with the corresponding buffer to 40 μ M, as Cu²⁺,Zn²⁺- and Cu⁺,Zn²⁺-SOD1, respectively. CD spectra were collected at 25 °C using a 1 mm path length cuvette on a JASCO J-725 spectropolarimeter.

2. Peptide mapping and MS analysis of ¹⁷O₂-oxidized SOD1

After oxidation with ¹⁷O₂ gas, the oxidation state and ¹⁷O-labeling ratio of ¹⁷O₂-oxidized SOD1 were confirmed by a previously reported procedure, using HPLC peptide-mapping analysis combined with ESI-TOF-MS analysis (Figure S1 and S2).¹ The ¹⁷O₂-oxidized SOD1 contains oxidized forms with Cys¹¹¹-SO₂H **2** and Cys¹¹¹-SO₃H **3**, as well as Cys¹¹¹-SH **1**. As described in experimental procedures section, the denatured ¹⁷O₂-oxidized SOD1 treated with iodoacetamide was submitted to limited proteolysis using lysylendopeptidase and was analyzed by HPLC (Figure S1b). The cocktail of ¹⁷O-oxidized peptide fragments contained peptides **5** (Cys¹¹¹-SH), **6**

(Cys¹¹¹-SO₂H), and **7** (Cys¹¹¹-SO₃H). As a control experiment, WT-SOD1 **1** was also digested by the same procedure, and the HPLC profile is shown in Figure S1a. The HPLC profile was almost identical to a previous report.¹ Two new peaks assigned as peptide **6** and **7** were identified, and the molar ratio of peptides **5**, **6**, and **7**, estimated by the corresponding peak areas, were 63:16:21. The two new peaks were collected and analyzed by high-resolution ESI-TOF-MS (Figure S2). As shown in Figure S2-1, the MS spectrum of peptide **5** provided a m/z of 830.9206, which corresponds to the tetravalent molecular ion peak [M+4H]⁴⁺ of peptide **5** (calcd 830.9252). Next, as shown in Figure S2-2, the MS profile of SO₂H-peptide **6** revealed m/z of 824.6656, which corresponds to the tetravalent molecular ion peak ([M+4H]⁴⁺ (calcd 824.6673). The peak-distribution was simulated and the ¹⁷O enrichment of peptide **6** was around 50%. Figure S2-3 shows the MS spectrum of RSO₃H-peptide **7**, giving a m/z of 828.6749. The value is in good agreement with the [M+4H]⁴⁺ ion peak of peptide **7** (calcd 828.6661). The ¹⁷O enrichment of peptide **7** was estimated to be 64%.

As described in the Experimental Section, 70% $^{17}O_2$ was employed for ^{17}O -labeling. However, the labeling rate of **6** and **7** did not reach 70%. The oxidation mechanism of SOD1 to form Cys¹¹¹-SO₂H and -SO₃H is not completely clear, but H₂¹⁶O in the buffer might be involved in the oxidative event by forming H-¹⁷O-¹⁶O-H at the superoxide degradation stage by SOD1 itself. Additionally, the ¹⁷O-labeling ratios of SO₂H-peptide **6** and SO₃H-peptide **7** showed a significant difference (50% and 64%). The different oxidation ratio may suggest that some active species with varying oxidation potentials are playing a role.

3. ¹H-NMR and CD spectra of ¹⁷O₂-oxidized SOD1 with Cu^{2+} , Zn^{2+} - and Cu^{+} , Zn^{2+} -states

¹H-NMR spectra as well as CD spectra of ¹⁷O₂-oxidized SOD1 with Cu²⁺ and Cu⁺ forms were measured (Figures S3, S4, and S5). In the superoxide degradation pathway of SOD1, reversible reduction/oxidation at the catalytic site Cu cation is essential. Overall protein structure was estimated by the patterns of the ¹H-NMR and CD spectra (Figure S3, S4 and S5). Local catalytic site structure in each Cu oxidation state was confirmed by the signal pattern on the imidazole NH protons of fingerprint His chelating the Zn and Cu cations (Figure S4).⁴ The ¹H-NMR signal, especially at 8 to 9 ppm originating from amide protons, showed significant differences between the Cu²⁺ and Cu⁺-forms (Figure S3). The CD spectra also support the significant difference in secondary structure (Figure S5).

The Cu^{2+} -form provided few signals in the reporter His region (11-16 ppm) because of the potent paramagnetic effect of the divalent Cu cation (Figure S4a). The observable signals shown in Figure S4a, are assigned as His43 $\varepsilon 2^4$, which is about 11 Å from the Cu^{2+} center, a distance usually long enough to eliminate paramagnetic effects.⁵ The Cu^{2+} paramagnetic effect was diminished under reductive conditions by addition of either 10 mM isoascorbic acid (Fig S4b) or 2-ME (Fig. S4c). The time course of the reduction was monitored by ¹H-NMR focusing on the reporter His region in each case. The Cu²⁺ in SOD1 was gradually reduced at 5 °C to give complete conversion to the Cu⁺ form within 4 h (data not shown). ¹H-NMR of the Cu⁺ state is shown in Figure S4b, providing a set of sharp metal ion-coordinating His signals (His71 £2; 15.4 ppm, His43 ε2; 14.0 ppm, His46 ε2; 13.4 ppm, His 43 δ1, 12.8 ppm, His80 ε2; 12.7 ppm, His63 ε2; 12.5 ppm, His48 δ1; 12.3 ppm). The assignment of the His signals was based on a previous report.⁴ Each Cys¹¹¹-oxidation form of **2** and **3** were not distinguishable from the SH form **1** in the ¹H-NMR spectral data. It suggests that the local conformation of the catalytic-site is not significantly different in the three oxidation states. This data is compatible with the finding that ¹⁶O₂-oxidized SOD1 is as active as wild-type SOD1.¹

Electronic Supplementary Material (ESI) for Chemical Communications This journal is The Royal Society of Chemistry 2013

4. Supporting figures



h

);

5,



Figure S2-1.

ESI-TOF MS profile of peptide **5** having amidomethyl-S-modification. $[M+4H]^{4+}$ region was expanded. (a) The spectrum of peptide **5**; (b) MS profile simulation of **5**.



Figure S2-2.

ESI-TOF MS profile of peptide **6**. $[M+4H]^{4+}$ region was expanded. (a) The spectrum of peptide **6**; (b) MS profile simulation of **6**. The differential MS distribution pattern indicates the ¹⁷O-labeling.



Figure S2-3.

ESI-TOF MS profile of peptide 7. The $[M+4H]^{4+}$ region is expanded. (a) The spectrum of peptide 7; (b) MS profile simulation of 7. The differential MS distribution pattern indicates the ¹⁷O-labeling. A contaminant in the S-alkylated form **5** was also found at m/z of 830.93.



Figure S3.

¹H-NMR spectra of ¹⁷O₂-oxidized SOD1 in 20 mM phosphate buffer composed with 10%D₂O (v/v) with pH of 5.0. (a) Cu²⁺-form, (b) Cu⁺-form prepared by an addition of 10 mM 2-ME, (c) digested peptide form. *; originating from (HO-CH₂-CH₂-S)₂. ^x; originating from HO-CH₂-CH₂-SH.



Figure S4.

¹H-NMR spectra of the fingerprint His regions of ¹⁷O₂-oxidized SOD1. (a) Cu^{2+} -form, (b) Cu^{+} -form prepared by addition of 10 mM isoascorbic acid, (c) Cu^{+} -form prepared by addition of 10 mM 2-ME (10 mM).

Figure S5.

CD spectra of Cu^{2+} -form (blue) and Cu^{+} -form (red), prepared by addition of 2-ME (10 mM), of $^{16}O_2$ -oxidized SOD1



5. References

- 1. N. Fujiwara, M. Nakano, S. Kato, D. Yoshihara, T. Ookawara, H. Eguchi, N. Taniguchi and K. Suzuki, *J. Biol. Chem.*, 2007, **282**, 35933.
- N. Fujiwara, Y. Miyamoto, K. Ogasahara, M. Takahashi, T. Ikegami, R. Takamiya, K. Suzuki and N. Taniguchi, *J. Biol. Chem.*, 2005, 280, 5061.
- 3. S. L. Patt, J. Magn. Reson., 1982, 49, 161.
- 4. L. Banci, I. Bertini, F. Cantini, N. D'Amelio and E. Gaggelli, *J. Biol. Chem.*, 2006, **281**, 2333.
- H. X. Deng, A. Hentati, J. A. Tainer, Z. Iqbal, A. Cayabyab, W. Y. Hung, E. D. Getzoff, P. Hu, B. Herzfeldt, R. P. Roos, C. Warner, G. Deng, E. Soriano, C. Smyth, H. E. Parge, A. Ahmed, A. D. Roses, R. A. Hallewell, M. A. Pericak-Vance and T. Siddique, *Science*, 1993, 261, 1047.